Background: Tuftsin activity (TA) is reduced in cirrhosis. This contributes to the defective phagocytic activity (PA) of neutrophil granulocytes and is related to the impairment of splenic function. Orthotopic liver transplantation (OLT) cures cirrhosis and might restore TA. This study was aimed at determining if OLT restores TA and PA. Methods: We measured in 9 cirrhotic patients, before and after successful OLT, TA by a bioassay and PA by chemiluminescence in which neutrophils of the patient were tested with both autologous (PA1) and pooled sera from healthy subjects (PA2). Splenic function was assayed by the pitted red cell count. Results: Before OLT, TA was reduced in 7 patients, and PA1 in all the patients. Pitted cell count was elevated in all the patients. After OLT (median 39 months; range 21–49), TA improved in all cases [median: from 8% (5–16%) to 20% (9–22%), p < 0.008], normalizing in 5 out of the 7 patients with low values. PA1 improved in all the patients [from 102 cpm (65–128 cpm) to 235 cpm (78–280 cpm), p < 0.008], normalizing in 5. Pitted red count decreased in 7 patients and normalized in 3 [from 3.3% (2.1–6.0%) to 2.4% (1.4–2.8%), p < 0.021]. Platelet count [from 55 × 103 (30–100) to 185 × 103 (93–286), p < 0.008] and leucocyte count [from 3.60 × 103 (1.81–5.23) to 5.53 × 103 (3.31–6.71), p < 0.008] also improved. Conclusions: OLT improves TA and PA of cirrhotic patients. This effect is associated with an improvement of both functional hyposplenism and haematological hypersplenism. The restoration of natural defences against infections may mitigate the adverse effect of immunosuppressive treatment.

1.
Najjar VA, Nishioka K: ‘Tuftsin’: A natural phagocytosis stimulating peptide. Nature 1970;228:672–673.
2.
Siemion IZ, Kluczyk A: Tuftsin: On the 30-year anniversary of Victor Najjar’s discovery. Peptides 1999;20:645–674.
3.
Constantopoulos A, Najjar VA, Wish JB, Necheles TH, Stolbach LL: Defective phagocytosis due to tuftsin deficiency in splenectomized subjects. Am J Dis Child 1973;125:663–665.
4.
Constantopoulos A, Likhite V, Crosby WH, Najjar VA: Phagocytic activity of the leukemic cell and its response to the phagocytosis-stimulating tetrapeptide, tuftsin. Cancer Res 1973;33:1230–1234.
5.
Spirer Z, Zakuth V, Diamant S, Mondorf W, Stefanescu T, Stabinsky Y, Fridkin M: Decreased tuftsin concentrations in patients who have undergone splenectomy. Br Med J 1977;2:1574–1576.
6.
Spirer Z, Weisman Y, Zakuth V, Fridkin M, Bogair N: Decreased serum tuftsin concentrations in sickle cell disease. Arch Dis Child 1980;55:566–567.
7.
Corazza GR, Zoli G, Ginaldi L, Cancellieri C, Profeta V, Gasbarrini G, Quaglino D: Tuftsin deficiency in AIDS. Lancet 1991;337:12–13.
8.
Zoli G, Corazza GR, Wood S, Bartoli R, Gasbarrini G, Farthing MJ: Impaired splenic function and tuftsin deficiency in patients with intestinal failure on long term intravenous nutrition. Gut 1998;43:759–762.
9.
Corazza GR, Zoli G, Di Sabatino A, Ciccocioppo R, Gasbarrini G: A reassessment of splenic hypofunction in celiac disease. Am J Gastroenterol 1999;94:391–397.
10.
Trevisani F, Castelli E, Foschi FG, Parazza M, Loggi E, Bertelli M, Melotti C, Domenicali M, Zoli G, Bernardi M: Impaired tuftsin activity in cirrhosis: Relationship with splenic function and clinical autcome. Gut 2002;50:707–712.
11.
Zoli G, Corazza GR, D’Amato G, Bartoli R, Baldoni F, Gasbarrini G: Splenic autotransplantation after splenectomy: Tuftsin activity correlates with residual splenic function. Br J Surg 1994;81:716–718.
12.
Najjar VA, Constantopoulos A: A new phagocytosis stimulating tetrapeptide hormone, tuftsin, and its role in disease. J Reticuloendothel Soc 1972;12:197–215.
13.
Piscaglia F, Zironi G, Gaiani S, Mazziotti A, Cavallari A, Gramantieri L, Valgimigli M, Bolondi L: Systemic and splanchnic hemodynamic changes after liver transplantation for cirrhosis: A long-term prospective study. Hepatology 1999;30:58–64.
14.
Rinkes IH, Van der Hoop AG, Hesselink EJ, Metselaar H, De Rave S, Zonderland HM, Schalm SW, Terpstra OT: Does auxiliary heterotopic liver transplantation reverse hypersplenism and portal hypertension? Gastroenterology 1991;100:1126–1128.
15.
Thorat SP, Thatte UM, Pai N, Dahanukar SA: Inhibition of phagocytes by cyclosporin in vitro. Q J Med 1994;87:311–314.
16.
Yoneyama K, Miyagishi K, Kiuchi Y, Shibata M, Mitamura K: Risk factors for infections in cirrhotic patients with and without hepatocellular carcinoma. J Gastroenterol 2002;37:1028–1034.
17.
Borzio M, Salerno F, Piantoni L, Cazzaniga M, Angeli P, Bissoli F, Boccia S, Colloredo-Mels G, Corigliano P, Fornaciari G, Marenco G, Pistara R, Salvagnini M, Sangiovanni A: Bacterial infection in patients with advanced cirrhosis: A multicentre prospective study. Dig Liver Dis 2001;33:41–48.
18.
Golfieri R, Giampalma E, Morselli Labate AM, d’Arienzo P, Jovine E, Grazi GL, Mazziotti A, Maffei M, Muzzi C, Tancioni S, Sama C, Cavallari A, Gavelli G: Pulmonary complications of liver transplantation: Radiological appearance and statistical evaluation of risk factors in 300 cases. Eur Radiol 2000;10:1169–1183.
19.
Troisi R, Colle I, Van Vlierberghe H, Hesse UJ, Cuomo O, de Hemptinne B: Splenectomy and liver transplantation. Transplant Proc 2001;33:1500–1501.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.